Silvia Deaglio

Peripheral blood CD38 expression predicts time to progression in B-cell chronic lymphocytic leukemia after first-line therapy with high-dose chlorambucil.

Human CD38 and CD16 are functionally dependent and physically associated in natural killer cells.

Oxytocin is a growth factor for Kaposi's sarcoma cells: evidence of endocrine-immunological cross-talk.

Arsenic trioxide and breast cancer: analysis of the apoptotic, differentiative and immunomodulatory effects.

Structural, functional, and tissue distribution analysis of human transferrin receptor-2 by murine monoclonal antibodies and a polyclonal antiserum.

Expression of ribosomal and translation-associated genes is correlated with a favorable clinical course in chronic lymphocytic leukemia.

Human CD38 interferes with HIV-1 fusion through a sequence homologous to the V3 loop of the viral envelope glycoprotein gp120.

Simultaneous expression of CD38 and its ligand CD31 by chronic lymphocytic leukemia B-cells: anecdotal observation or pathogenetic hypothesis for the clinical outcome?

Role of CD31/platelet endothelial cell adhesion molecule-1 expression in in vitro and in vivo growth and differentiation of human breast cancer cells.

CD38 ligation plays a direct role in the induction of IL-1beta, IL-6, and IL-10 secretion in resting human monocytes.

CD38 is a signaling molecule in B-cell chronic lymphocytic leukemia cells.

Death of T cell precursors in the human thymus: a role for CD38.

Transferrin receptor 2 protein is not expressed in normal erythroid cells.

CD38 and CD100 lead a network of surface receptors relaying positive signals for B-CLL growth and survival.

Immunodetection of anti-MAG IgM antibody by cross-reactivity to LA-N-1 neuroblastoma cells.

CD38 orchestrates migration, survival, and Th1 immune response of human mature dendritic cells.

In-tandem insight from basic science combined with clinical research: CD38 as both marker and key component of the pathogenetic network underlying chronic lymphocytic leukemia.

TfR2 localizes in lipid raft domains and is released in exosomes to activate signal transduction along the MAPK pathway.

CD38/CD19: a lipid raft-dependent signaling complex in human B cells.

CD38 and CD157 as receptors of the immune system: a bridge between innate and adaptive immunity.

The CD38 ectoenzyme family: advances in basic science and clinical practice.

Transferrin receptor 2 is frequently expressed in human cancer cell lines.

Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression.

Prognostic significance of combined analysis of ZAP-70 and CD38 in chronic lymphocytic leukemia.

CD38 and ZAP-70 are functionally linked and mark CLL cells with high migratory potential.

Regulation of CD38 in proliferating chronic lymphocytic leukemia cells stimulated with CD154 and interleukin-4.

CD38 at the junction between prognostic marker and therapeutic target.

CD39 and control of cellular immune responses.

The CD38/CD157 mammalian gene family: An evolutionary paradigm for other leukocyte surface enzymes.

CD38 gene polymorphism and chronic lymphocytic leukemia: a role in transformation to Richter syndrome?

Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology.

Regulation of transferrin receptor 2 in human cancer cell lines.

CD38 and CD157 ectoenzymes mark cell subsets in the human corneal limbus.

CD38/CD31, the CCL3 and CCL4 chemokines, and CD49d/vascular cell adhesion molecule-1 are interchained by sequential events sustaining chronic lymphocytic leukemia cell survival.

Chronic lymphocytic leukemia microenvironment: shifting the balance from apoptosis to proliferation.

Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome.

Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance.

TfR2 expression in human colon carcinomas.

CD38/CD31 interactions activate genetic pathways leading to proliferation and migration in chronic lymphocytic leukemia cells.

Genetic modification of primary chronic lymphocytic leukemia cells with a lentivirus expressing CD38.

Monocytes/macrophages but not T lymphocytes are the major targets of the CCL3/CCL4 chemokines produced by CD38(+)CD49d(+) chronic lymphocytic leukaemia cells.

Transferrin receptor 2 is frequently and highly expressed in glioblastomas.

The hidden life of NAD+-consuming ectoenzymes in the endocrine system.

Multicentre validation of a prognostic index for overall survival in chronic lymphocytic leukaemia.

CD38 as a molecular compass guiding topographical decisions of chronic lymphocytic leukemia cells.

Chronic lymphocytic leukemia-associated immune thrombocytopenia treated with rituximab: a retrospective study of 21 patients.

Regulatory T-cell number is increased in chronic lymphocytic leukemia patients and correlates with progressive disease.

Variable impact of CD39 in experimental murine colitis.

A variant of the LRP4 gene affects the risk of chronic lymphocytic leukaemia transformation to Richter syndrome.

Oct-4+/Tenascin C+ neuroblastoma cells serve as progenitors of tumor-derived endothelial cells.

NAD+-metabolizing ecto-enzymes shape tumor-host interactions: the chronic lymphocytic leukemia model.

A highly immunogenic recombinant and truncated protein of the secreted aspartic proteases family (rSap2t) of Candida albicans as a mucosal anticandidal vaccine.

Common genetic variation at 15q25.2 impacts on chronic lymphocytic leukaemia risk.

Nicotinamide blocks proliferation and induces apoptosis of chronic lymphocytic leukemia cells through activation of the p53/miR-34a/SIRT1 tumor suppressor network.

Ectonucleotidases as regulators of purinergic signaling in thrombosis, inflammation, and immunity.

CD38 and chronic lymphocytic leukemia: a decade later.

Alteration of BIRC3 and multiple other NF-κB pathway genes in splenic marginal zone lymphoma.

CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death.

Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness.

Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia.

Physical contact with endothelial cells through β1- and β2- integrins rescues chronic lymphocytic leukemia cells from spontaneous and drug-induced apoptosis and induces a peculiar gene expression profile in leukemic cells.

Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia.

A shorter time to the first treatment may be predicted by the absolute number of regulatory T-cells in patients with Rai stage 0 chronic lymphocytic leukemia.

Microenvironmental interactions in chronic lymphocytic leukemia: hints for pathogenesis and identification of targets for rational therapy.

Different aquaporin-4 expression in glioblastoma multiforme patients with and without seizures.

The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development.

Targeting the microenvironment in chronic lymphocytic leukemia offers novel therapeutic options.

Regulatory T-cells in chronic lymphocytic leukemia and autoimmune diseases.

Chronic lymphocytic leukemia after chronic myeloid leukemia in the same patient: two different genomic events and a common treatment?

Biological functions of ecto-enzymes in regulating extracellular adenosine levels in neoplastic and inflammatory disease states.

The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia.

The monocytic population in chronic lymphocytic leukemia shows altered composition and deregulation of genes involved in phagocytosis and inflammation.

rs2072135, a low-penetrance variant for chronic lymphocytic leukaemia?

Complementary and alternative medicine use in patients with chronic lymphocytic leukemia: an Italian multicentric survey.

Multiple metamorphoses of CD38 from prognostic marker to disease modifier to therapeutic target in chronic lymphocytic leukemia.

HLA-G is a component of the chronic lymphocytic leukemia escape repertoire to generate immune suppression: impact of the HLA-G 14 base pair (rs66554220) polymorphism.

Anti-CD44 mAb for the treatment of B-cell chronic lymphocytic leukemia and other hematological malignancies: evaluation of WO2013063498.

Extracellular nicotinamide phosphoribosyltransferase (NAMPT) promotes M2 macrophage polarization in chronic lymphocytic leukemia.

Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia.

Identification of a new subclass of ALK-negative ALCL expressing aberrant levels of ERBB4 transcripts.

SLAMF1 regulation of chemotaxis and autophagy determines CLL patient response.

Involvement of the P2X7-NLRP3 axis in leukemic cell proliferation and death.

miR-214 and miR-148b targeting inhibits dissemination of melanoma and breast cancer.

The genetics of nodal marginal zone lymphoma.